TBPN The Great Peptide Debate with Martin Shkreli & Max Marchione
83 snips
Mar 23, 2026 
Max Marchione, a healthcare founder at Superpower, faces Martin Shkreli, a controversial former pharma executive, in a sharp peptide showdown. They spar over BPC-157, retatrutide, gray-market sourcing, compounding, off-label use, and whether anecdotes should challenge gold-standard trials. The real tension is access versus control, and whether regulation should bend or hold firm.
AI Snips
Chapters
Transcript
Episode notes
The Debate Starts With What Counts As A Peptide
- Martin Shkreli argues peptides are an old, weak drug class that pharma usually avoids, while Max Marchione says GLP-1s proved peptides can be world-changing despite earlier skepticism.
- Their first fault line is not all peptides, but gray-market use of unapproved compounds like retatrutide versus waiting for FDA approval or using approved GLP-1s.
Gray Market Versus White Market Is The Real Fight
- Max Marchione argues the core policy choice is not use versus no use, but gray market versus regulated compounding for peptides people already take at scale.
- He points to BPC-157 and says moving certain compounds from category two to category one would reduce supply-chain risk and doctorless experimentation.
Twenty Doctor Conversations Flipped Max Marchione
- Max Marchione says he went from peptide skeptic to believer after asking about 20 doctors he respected, and nearly all told him they used peptides in patients.
- He contrasts that with nutrition debates where doctors split sharply, saying peptide conversations were unusually aligned around clinical usefulness.